Experts discuss complex hypothetical patient case scenarios in non–small cell lung cancer (NSCLC), highlighting current screening and testing methodologies, diagnostic challenges, and best practices in management.
Two expert oncologists discuss the critical role of comprehensive biomarker testing in non-small cell lung cancer (NSCLC). They emphasize that molecular testing is an essential part of the initial diagnosis, not an optional add-on, as it identifies specific mutations and fusions that dictate the most effective first-line treatment.
The oncologists delve into the specifics of which non-small cell lung cancer (NSCLC) patients to test. They recommend testing all non-squamous cases and, increasingly, squamous cases as well, especially those with a light smoking history, to ensure no actionable biomarker is missed.
The oncologists delve into the specifics of which non-small cell lung cancer (NSCLC) patients to test. They recommend testing all non-squamous cases and, increasingly, squamous cases as well, especially those with a light smoking history, to ensure no actionable biomarker is missed.
The oncologists delve into the specifics of which non-small cell lung cancer (NSCLC) patients to test. They recommend testing all non-squamous cases and, increasingly, squamous cases as well, especially those with a light smoking history, to ensure no actionable biomarker is missed.
Experts discuss treatment options for stage III non-small cell lung cancer (NSCLC) without actionable driver mutations and with a PD-L1 expression of 30%. The experts emphasize a multidisciplinary evaluation to decide between a surgical or non-surgical approach.
Experts address managing recurrent non-small cell lung cancer (NSCLC) after definitive treatment with surgery and immunotherapy (IO). The experts outline a strategy based on the timing of recurrence.
Experts discuss the critical importance of including RNA sequencing in comprehensive biomarker testing for non-small cell lung cancer (NSCLC). They highlight that while DNA-based NGS is foundational, it is insufficient for reliably detecting key gene fusions like RET and ROS1
Experts address a complex case of a never-smoker with early-stage non-small cell lung cancer (NSCLC). The diagnosis is complicated by ambiguous neuroendocrine markers on the biopsy, a PD-L1 score of 0%, and a negative NGS panel for common drivers, which is unusual for a never-smoker.
Experts discuss how to manage a complex non-small cell lung cancer (NSCLC) case with ambiguous neuroendocrine markers and initially negative biomarker testing. They note that mixed biphenotypic tumors are not uncommon but present a diagnostic challenge.
Experts discuss how the final pathology report, which included an RNA-based NGS test, definitively resolved the case by identifying a RET fusion. They highlight this finding as a critical justification for comprehensive biomarker testing, especially in never-smoker patients where initial results are negative.
Experts address the critical differences between pre-operative biopsies and post-operative surgical specimens for biomarker testing. They confirm that a surgical specimen is far more reliable, as it provides a larger, higher-quality sample, allowing a pathologist to select a more tumor-rich area for analysis. This was key in finally identifying the patient's RET fusion.
Experts emphasize the indispensable role of a multidisciplinary team (MDT) in managing non-small cell lung cancer (NSCLC). They highlight that complex cases, like the one discussed, demonstrate how knowledge evolves and how critical collaborative decision-making is for optimal patient outcomes.
Experts discuss the critical factors for recommending adjuvant chemotherapy after surgery for early-stage non-small cell lung cancer (NSCLC). They confirm that lymph node involvement (N1 disease) is a clear indicator for offering platinum-based chemotherapy due to the higher risk of recurrence.
In their concluding remarks, the experts highlight critical future directions and unmet needs in non-small cell lung cancer (NSCLC). A major focus is on improving lung cancer screening. They note that current screening rates are unacceptably low (~20%) and emphasize the need to better integrate it into primary care. Furthermore, they call for expanded screening criteria to include populations not currently eligible, such as never-smokers and light smokers, especially women, who are increasingly being diagnosed.
